登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式(希尔记法):
C22H28N2O6
化学文摘社编号:
分子量:
416.47
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
Quality Segment
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
off-white
solubility
ethanol: 15 mg/mL, DMSO: 30 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
N(O)C(=O)[C@H](C[C@H](NC(=O)c1ccc(cc1)Oc2ccccc2)COCOCC)C
InChI
1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1
InChI key
HDWWQELUBWGQGA-WMZOPIPTSA-N
General description
An orally active non-peptidyl hydroxamate compound that acts as an effective broad-spectrum inhibitor against MMP-2, -3, -8, -9, -12, -13 (Ki = 0.73, 42, 1.1, 2.1, 0.45, and 1.1 nM, respectively), but not MMP-1 (IC50 = 1.6 µM), MMP-7 (Ki = 2.5 µM), or other serine proteases (no activity against chymotrypsin or plasmin at 100 µM). Widely used in studying MMP-mediated diseases development in vivo. Also reported to block P-LAP secretase activity (≥70% inhibition of P-LAP shedding at 10 µM) that is otherwise not inhibited by TIMP-1/2 in CHO cell cultures in vitro.
Packaging
Packaged under inert gas
Other Notes
Okamoto, Y., et al. 2007. Int. Heart J.48, 369.
Ito, N., et al. 2004. Biochem. Biophys. Res. Commun.314, 1008.
Shiraga, M., et al. 2002. Cancer Res.62, 5967.
Mori, T., et al. 2001. Exp. Biol. Med.226, 429.
Yamada, A., et al. 2000. Inflamm. Res.49, 144.
Ito, N., et al. 2004. Biochem. Biophys. Res. Commun.314, 1008.
Shiraga, M., et al. 2002. Cancer Res.62, 5967.
Mori, T., et al. 2001. Exp. Biol. Med.226, 429.
Yamada, A., et al. 2000. Inflamm. Res.49, 144.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable